Jeb Keiper, Nimbus CEO
August 17, 2021 10:53 AM EDT
R&D
Pharma

Next-gen pso­ri­a­sis drug ri­val­ry be­tween Bris­tol My­ers and Nim­bus spills in­to a le­gal bat­tle

Zachary Brennan

Senior Editor

When Bris­tol My­ers Squibb de­cid­ed to ac­quire Cel­gene for $80 bil­lion in 2019, the two were forced to di­vest pso­ri­a­sis drug Ote­zla to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times